BlueBird Bio, Inc., Former High-Flyer, has Crashed to Earth

Drug prospects dwindling, cash runway now drying up, abandoned by management, all while attempting to retain an investor base with false hopes driven by misleading statements Bluebird bio (NASDAQ:BLUE), once a darling of the pre-revenue hot-biotech-money crowd, has entered its death spiral. Access to capital for bringing any product to market becomes increasingly dilutive and forces management into additional stock ...
Read More